Development of novel melatonin-isatin hybrids as multifunctional agents for Alzheimer’s disease
Molecular Diversity · 2025-12 · 29 (6) · 6363-6378
DOI: 10.1007/s11030-025-11129-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, online erschienen am 04.03.2025. Verfasst von Ying-Ying Zhong und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Guangdong Medical University, Dongguan, 523808, Guangdong, China. Hauptthemen laut MEDLINE: Melatonin, Alzheimer Disease, Neuroprotective Agents, Isatin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: the research funds of the Students' Innovative Program of Guangdong Medical University, Guangdong Province Medical Research Foundation, Zhanjiang science and technology project.
Themen: Demenz
Abstract (Originalsprache)
The development of multifunctional agents has been a heated area of research for AD treatment in recent years. In this work, a series of melatonin-isatin hybrids were designed, synthesized, and evaluated as multifunctional agents for treating AD. In vitro studies indicated that most of the synthesized compounds displayed moderate to good MAO-B inhibition activities and good antioxidant activities. In particular, compounds IM-5 and IM-10 exhibited the best inhibitory activities with IC50 value of 12.4 μM and 15.6 μM against MAO-B, and potent antioxidant activities with their ORAC-FL values of 4.6 and 5.2 at 5 μM, respectively. ThT assay revealed compounds IM-5 and IM-10 exhibited the optimal Aβ1-42 self-induced aggregation inhibitory activities with the inhibition ratio of 72.8% and 69.7% at 20 μM. In addition, compounds IM-5 and IM-10 exhibited low cytotoxicities and significant neuroprotective effects on Aβ1-42-induced and H2O2-induced SH-SY5Y cell injury. More importantly, compounds IM-5 and IM-10 could significantly ameliorate the memory impairment and cognition injury in scopolamine-induced mice. The SwissADME program was used to predict drug-like properties of compounds IM-5 and IM-10 which exhibited they had good pharmacokinetics and drug-likeness properties. Molecular docking study further manifested that compounds IM-5 and IM-10 showed high hMAO-B inhibitory potency. In summary, all above results revealed compounds IM-5 and IM-10 might be promising multifunctional agents for AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Guangdong Medical University, Dongguan, 523808, Guangdong, China.
- School of Pharmacy, Guangdong Medical University, Dongguan, 523808, Guangdong, China. wangxqhb@163.com.
- School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, 529020, China.
- School of Pharmacy, Guangdong Medical University, Dongguan, 523808, Guangdong, China. wangxqgdmu@hotmail.com.
Förderung
- the research funds of the Students' Innovative Program of Guangdong Medical University
- Guangdong Province Medical Research Foundation
- Zhanjiang science and technology project
- the research funds of the Doctoral Program of Guangdong Medical University
- the National Natural Science Foundation of China
- the research funds of the Students’ Innovative Program of Guangdong Medical University
Zitieren
APA
Zhong, Y. Y., Deng, J. Z., Wang, Q., Chen, L., Yang, Z. H., Zhang, Y. M., Zhou, L. Y., Li, Y. R., Wu, J. Q., & Wang, X. Q. (2025). Development of novel melatonin-isatin hybrids as multifunctional agents for Alzheimer’s disease. Molecular Diversity, 29(6), 6363-6378. https://doi.org/10.1007/s11030-025-11129-2
Vancouver
Zhong YY, Deng JZ, Wang Q, Chen L, Yang ZH, Zhang YM, et al. Development of novel melatonin-isatin hybrids as multifunctional agents for Alzheimer’s disease. Molecular Diversity. 2025;29(6):6363-6378. doi:10.1007/s11030-025-11129-2
BibTeX
@article{Zhong2025,
author = {Zhong, Ying-Ying and Deng, Jun-Ze and Wang, Qin and Chen, Li and Yang, Zi-Hang and Zhang, Ya-Mei and Zhou, Lu-Yi and Li, Yi-Ran and Wu, Jia-Qiang and Wang, Xiao-Qin},
title = {Development of novel melatonin-isatin hybrids as multifunctional agents for Alzheimer’s disease},
journal = {Molecular Diversity},
year = {2025},
volume = {29},
number = {6},
pages = {6363--6378},
doi = {10.1007/s11030-025-11129-2}
}
EUVIMED